RPG Active Pharma to buy Raghava's API business for up to Rs 135 crores via slump sale

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

RPGLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.7%Reaction day

₹2565.10

prior close

₹2596.90

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.6%+3.1% vs market

Pharmaceuticals peers, median of 172sector+0.3%+3.3% vs sector

On the reaction day the stock moved 3.1 pts more than Nifty Microcap 250 and 3.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.1

15m

-0.5

30m

+1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.7+0.6+3.1+0.3+3.3

Next day

+6.0+1.3+4.8+0.2+5.8

+3.9+1.7+2.2+0.8+3.1

+11.1+2.2+8.9+1.1+10.0

+9.0+2.1+6.9+0.6+8.4

+8.4+1.9+6.5+0.8+7.6

+8.0-1.3+9.3-1.1+9.1

15d

+19.1+1.3+17.8+0.8+18.3

+13.3-0.8+14.1-2.2+15.5

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

RPG Life Sciences' subsidiary RPG Active Pharma will buy Raghava Life Sciences' API and Intermediates business via slump sale for up to Rs 135 crores cash. Target had revenue of about Rs 19 crores in FY26, with 29 API molecules (22 commercialized, 7 in development), manufacturing and R&D facilities. Not a related party deal. Expected to close in 30 days, subject to approvals. Supports the company's API expansion strategy.

Likely market impact

Positive move to scale up API business. Non-organic, but supports growth in core pharma segment. Watch for closure and any margin impact.